
ADC Therapeutics Unveils Exciting New Research at 66th ASH Annual Meeting
ADC Therapeutics Presents Promising Results in Phase 2 Study at ASH Annual Meeting ADC Therapeutics SA, a global leader in antibody drug conjugates, recently shared exciting news regarding their investigational drug ZYNLONTA®. The company announced that abstracts from an investigator-initiated Phase 2 study evaluating ZYNLONTA in combination with rituximab have been accepted for presentation at…